These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7810345)

  • 21. Predictors of the course of tardive dyskinesia in patients receiving neuroleptics.
    Bergen J; Kitchin R; Berry G
    Biol Psychiatry; 1992 Oct; 32(7):580-94. PubMed ID: 1360260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic dyskinesia examination of profoundly mentally retarded persons: cooperation and assessment.
    Granger DA; Yurkunski JM; Miller NH; Swanson JM; Crinella FC
    Am J Ment Defic; 1987 Sep; 92(2):155-60. PubMed ID: 2893551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The motor disorders of mental handicap. An overlap with the motor disorders of severe psychiatric illness.
    Rogers D; Karki C; Bartlett C; Pocock P
    Br J Psychiatry; 1991 Jan; 158():97-102. PubMed ID: 2015458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions.
    Dean CE; Kuskowski MA; Caligiuri MP
    J Clin Psychopharmacol; 2006 Dec; 26(6):560-5. PubMed ID: 17110811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Negative symptoms as a risk factor for tardive dyskinesia in schizophrenia.
    Liddle PF; Barnes TR; Speller J; Kibel D
    Br J Psychiatry; 1993 Dec; 163():776-80. PubMed ID: 7905774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of late-life schizophrenia with neuroleptics.
    Jeste DV; Lacro JP; Gilbert PL; Kline J; Kline N
    Schizophr Bull; 1993; 19(4):817-30. PubMed ID: 7905663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tardive dyskinesia in older out-patients: a follow-up study.
    Labbate LA; Lande RG; Jones F; Oleshansky MA
    Acta Psychiatr Scand; 1997 Sep; 96(3):195-8. PubMed ID: 9296550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III.
    van Harten PN; Hoek HW; Matroos GE; Koeter M; Kahn RS
    Am J Psychiatry; 1998 Apr; 155(4):565-7. PubMed ID: 9546009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orofacial dyskinesia, cognitive function and medication.
    Thomas P; McGuire R
    Br J Psychiatry; 1986 Aug; 149():216-20. PubMed ID: 2877703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to examine patients using the Abnormal Involuntary Movement Scale.
    Munetz MR; Benjamin S
    Hosp Community Psychiatry; 1988 Nov; 39(11):1172-7. PubMed ID: 2906320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroleptic-induced respiratory dyskinesia.
    Kruk J; Sachdev P; Singh S
    J Neuropsychiatry Clin Neurosci; 1995; 7(2):223-9. PubMed ID: 7626967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lifetime antipsychotic-drug exposure, dyskinesia and related movement disorders in the developmentally disabled.
    Stone RK; Alvarez WF; Ellman G
    Pharmacol Biochem Behav; 1989 Dec; 34(4):759-63. PubMed ID: 2576142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Tardive dyskinesia. A possible complication of chronic treatment with neuroleptics].
    D'Aquila F; Rampello L
    Riv Neurol; 1990; 60(4):140-5. PubMed ID: 1982720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Never treated schizophrenic patients have no abnormal movements such as tardive dyskinesia].
    Chorfi M; Moussaoui D
    Encephale; 1985; 11(6):263-5. PubMed ID: 2869939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tardive dyskinesia and other drug-induced movement disorders among handicapped children and youth.
    Gualtieri CT; Hawk B
    Appl Res Ment Retard; 1980; 1(1-2):55-69. PubMed ID: 6121532
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug-induced movement disorders in institutionalised adults with mental retardation: clinical characteristics and risk factors.
    Sachdev P
    Aust N Z J Psychiatry; 1992 Jun; 26(2):242-8. PubMed ID: 1353672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurobehavioral assessment of children and adolescents attending a developmental disabilities clinic.
    Brasić JR; Barnett JY; Kowalik S; Tsaltas MO; Ahmad R
    Psychol Rep; 2004 Dec; 95(3 Pt 2):1079-86. PubMed ID: 15762388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The abrupt withdrawal of antiparkinsonian drugs in mentally handicapped patients.
    Carter G
    Br J Psychiatry; 1983 Feb; 142():166-8. PubMed ID: 6132644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tardive dyskinesia: who is at risk?
    van Os J; Fahy T; Jones P; Harvey I; Toone B; Murray R
    Acta Psychiatr Scand; 1997 Sep; 96(3):206-16. PubMed ID: 9296552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of severe and mild tardive dyskinesia: implications for etiology.
    Gardos G; Cole JO; Schniebolk S; Salomon M
    J Clin Psychiatry; 1987 Sep; 48(9):359-62. PubMed ID: 2887550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.